FDA Will Fund Research On “Critical Path” Of Drug Development
Executive Summary
FDA's "Critical Path" initiative will redirect the agency's research funding towards identifying and alleviating some major barriers to drug development
You may also be interested in...
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected
European Union And Industry Launch Massive Pharmaceutical R&D Program
The European Commission and European drug makers have agreed to spend €2 billion, almost $3 billion, to develop technologies that can speed the development and delivery of new drugs to patients